Literature DB >> 21212433

Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Rebecca Anne Miksad1, Kuan-Chi Lai, Thomas Benton Dodson, Sook-Bin Woo, Nathaniel Simon Treister, Omosalewa Akinyemi, Marian Bihrle, Guy Maytal, Meredith August, G Scott Gazelle, J Shannon Swan.   

Abstract

PURPOSE: Potentially debilitating, osteonecrosis of the jaw (ONJ) is an emerging complication of bisphosphonates. However, its effect on quality of life (QoL) is unknown. We determined the ONJ-related QoL decline in a cancer patient cohort. PATIENTS AND METHODS: Thirty-four cancer patients with bisphosphonate-associated ONJ completed a telephone survey (October 2007 through May 2008). The Oral Health Impact Profile 14 (OHIP) retrospectively assessed participant oral health-related QoL before and after ONJ. Standardized ONJ descriptions were developed in a multidisciplinary, iterative process and were evaluated with three frequently used preference-based QoL measurement methods on a 0 (death) to 1 (perfect health) scale: Visual Analogue Scale (VAS), Time Trade-Off (TTO), and EQ-5D.
RESULTS: ONJ significantly (p < .001) increased OHIP scores (worse QoL) for additive (3.56-16.53) and weighted (7.0-17.5) methods. Seven individual OHIP items significantly increased (Bonferroni correction p < .0035): pain, eating discomfort, self-consciousness, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction. Mean preference-based QoL values significantly decreased (p < .001) with worsening ONJ stage (VAS, TTO, and EQ-5D): no ONJ (0.76, 0.86, 0.82), ONJ stage 1 (0.69, 0.82, 0.78), ONJ stage 2 (0.51, 0.67, 0.55), and ONJ stage 3 (0.37, 0.61, 0.32). As ONJ worsened, EQ-5D domain scores significantly increased (p < .001). Pain/discomfort and anxiety/depression contributed most to declining QoL.
CONCLUSIONS: ONJ significantly affects QoL, a detriment that increases with worsening ONJ. QoL impairments for ONJ stages 2 and 3 are similar to other treatment side effects that influence decision-making. Bisphosphonate-associated ONJ QoL is an important consideration for patients, clinicians, and policy makers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212433      PMCID: PMC3228058          DOI: 10.1634/theoncologist.2010-0183

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  90 in total

1.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

2.  Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

Authors:  Alessandro M Vannucchi; Giuseppe Ficarra; Elisabetta Antonioli; Alberto Bosi
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

3.  Reliability and validity of two oral health related quality of life measures in Myanmar adolescents.

Authors:  K K Soe; S Gelbier; P G Robinson
Journal:  Community Dent Health       Date:  2004-12       Impact factor: 1.349

4.  The comparability and reliability of five health-state valuation methods.

Authors:  P F Krabbe; M L Essink-Bot; G J Bonsel
Journal:  Soc Sci Med       Date:  1997-12       Impact factor: 4.634

5.  Utilities for prostate cancer health states in men aged 60 and older.

Authors:  Susan T Stewart; Leslie Lenert; Vibha Bhatnagar; Robert M Kaplan
Journal:  Med Care       Date:  2005-04       Impact factor: 2.983

6.  Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Authors:  S J Ackerman; E M Sullivan; K M Beusterien; H M Natter; D F Gelinas; D L Patrick
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

7.  Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.

Authors:  D G Fryback; W F Lawrence
Journal:  Med Decis Making       Date:  1997 Jul-Sep       Impact factor: 2.583

8.  Derivation and validation of a short-form oral health impact profile.

Authors:  G D Slade
Journal:  Community Dent Oral Epidemiol       Date:  1997-08       Impact factor: 3.383

9.  Do item weights matter? An assessment using the oral health impact profile.

Authors:  P F Allen; D Locker
Journal:  Community Dent Health       Date:  1997-09       Impact factor: 1.349

10.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.

Authors:  T Saarto; C Blomqvist; M Välimäki; P Mäkelä; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  49 in total

1.  Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.

Authors:  Sara de Cassia Tornier; Fernanda Joly Macedo; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  Support Care Cancer       Date:  2021-05-10       Impact factor: 3.603

2.  Aggressive denosumab-related jaw necrosis - a case series.

Authors:  M Badr; E Kyriakidou; S Atkins; S Harrison
Journal:  Br Dent J       Date:  2017-07-07       Impact factor: 1.626

3.  Legal liability in bisphosphonate-related osteonecrosis of the jaw.

Authors:  L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

4.  Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.

Authors:  Paola Nicoletti; Vassiliki M Cartsos; Penelope K Palaska; Yufeng Shen; Aris Floratos; Athanasios I Zavras
Journal:  Oncologist       Date:  2012-01-20

5.  The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.

Authors:  Daniel H Solomon; Amanda R Patrick; John Schousboe; Elena Losina
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

6.  Osseous changes in patients with medication-related osteonecrosis of the jaws.

Authors:  Zeynep Burcin Gönen; Canay Yillmaz Asan; Gökmen Zararsiz; Erdem Kiliç; Alper Alkan
Journal:  Dentomaxillofac Radiol       Date:  2017-11-01       Impact factor: 2.419

7.  Bisphosphonate-related osteonecrosis of the jaws: legal liability from the perspective of the prescribing physician.

Authors:  Lucio Lo Russo; Lorenzo Lo Muzio; Claudio Buccelli; Pierpaolo Di Lorenzo
Journal:  J Bone Miner Metab       Date:  2013-07-09       Impact factor: 2.626

8.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

9.  Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw.

Authors:  M S Najm; D H Solomon; S-B Woo; N S Treister
Journal:  Oral Dis       Date:  2013-02-19       Impact factor: 3.511

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.